Effective protection of mice against Shigella flexneri with a new self-adjuvant multicomponent vaccine.

CONCLUSION: The convenient and safe manufacturing process, and the preliminary biological evaluation, support the use of the self-adjuvanted HT complex as a new vaccine candidate to face shigellosis. Further development is required, such as additional immune analyses, to evaluate whether this new subunit vaccine can be useful in achieving full protection against Shigella. PMID: 28721849 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28721849?dopt=Abstract

Source: Journal of Medical Microbiology - July 18, 2017 Category: Microbiology Authors: Pastor Y, Camacho A, Gil AG, Ramos R, Ceráin AL, Peñuelas I, Irache JM, Gamazo C Tags: J Med Microbiol Source Type: research